Drug-Induced Hemolytic Anemia – Decision Support Tool
Drug-Induced Hemolytic Anemia – Decision Support (HCP)
Triage • Timing • Hemolysis evidence • Mechanism • Severity • Causality • Regulatory • Actions • Summary
1) Patient, Drug & Timing
Days start → onset
–
Risk window
–
Drug-class–informed
Known association
–
Penicillins, cephalosporins, quinidine, methyldopa, NSAIDs, oxidants (primaquine, dapsone, nitrofurantoin)
2) Hemolysis – Labs & Findings
Hemolysis evidence
–
Severity / urgency
–
Emergency flags
–
Suggested immediate actions:
Mechanism • Causality • Regulatory • Alt. causes • Summary
Mechanism lean
–
Timing class
–
Drug-class expectations
Culprit class
–
Causality – Quick (WHO-UMC / Naranjo-inspired)
Causality score: 0
Result: –
Auto adds +1 biologic plausibility if DAT positive or (G6PD deficient + oxidant drug).
Regulatory Reporting – Reportability Aid
Use label/IB per SOP.
Reportability
–
Expedited timeline
–
Indicative; verify local rules/SOPs
Due by (from awareness)
–
Many regions expedite serious + unexpected post-marketing cases (~15 days). In trials, serious + unexpected suspected reactions are SUSARs (fatal/life-threatening ~7 days; others ~15 days). Always follow your SOP/regional rules.
Alternative explanations (checklist)
- Infections (e.g., malaria), sepsis/DIC.
- Autoimmune hemolytic anemia (primary; cold agglutinin disease).
- Hereditary: sickle cell, thalassemia, hereditary spherocytosis.
- MAHA (TTP/HUS), prosthetic valve/mechanical hemolysis.
- G6PD deficiency (baseline) with non-drug triggers (e.g., fava beans).
Auto-generated Case Summary
Disclaimer: Decision support only; does not replace clinical judgment, specialist input, or local SOPs/regulations. Causality/urgency heuristics are simplified aids.
